Papers: 29 Oct 2012 - 5 Nov 2012
Soluble axoplasm enriched from injured CNS axons reveals the early modulation of the actin cytoskeleton.
Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.
Preliminary study on the association of AQP4 promoter polymorphism with anti-aquaporin-4 antibody positivity in Southern Han Chinese patients with idiopathic demyelinating disorders of central nervous system.
Antenarratives to inform health care research: exploring workplace illness disclosure for people with multiple sclerosis (MS).
Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
Constraint-Induced Movement Therapy for the Lower Extremities in Multiple Sclerosis: Case Series with 4-Year Follow-up.
Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis.
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Resident glial cell activation in response to perispinal inflammation leads to acute changes in nociceptive sensitivity: implications for the generation of neuropathic pain.
Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis.
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?
Consequences of neurologic lesions assessed by Barthel Index after Botox(®) injection may be underestimated.
Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters.
Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases.